HUMAN-MURINE CHIMERIC ANTIBODIES VS. RESPIRATORY SYNCYTIAL VIRUS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 18917
Amount: $428,150.00
Phase: Phase II
Program: SBIR
Awards Year: 1993
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Medimmune Inc.
19 Firstfield Road, Gaithersburg, MD, 20878
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Leslie S Johnson
 (301) 417-0770
Business Contact
Phone: () -
Research Institution
N/A
Abstract
RESPIRATORY SYNCYTIAL VIRUS (RSV) IS RESPONSIBLE FOR YEARLY EPIDEMICS OF BRONCHIOLITIS AND PNEUMONIA IN INFANTS AND YOUNG CHILDREN. AT RISK OF SERIOUS RSV MORBIDITY ARE CHILDREN WITH UNDERLYING DISEASE, BRONCHOPULMONARY DYSPLASIA AND OTHER PULMONARY DISEASES, VARIOUS CONGENITALOR ACQUIRED IMMUNODEFICIENCY SYNDROMES AND PREMATURITY. A VACCINE FOR IMMUNIZATION TO PREVENT RSV INFECTIONS IS URGENTLY NEEDED. UNFORTUNATELY, RSV VACCINES ARE UNLIKELY TO BE LICENSED IN THE NEAR FUTURE. THE INITIAL FORMALIN INACTIVATED RSV VACCINE CAUSED AN INCREASED INCIDENCE OFRSV LOWER RESPIRATORY TRACT DISEASE AND DEATH IN IMMUNIZED CHILDREN. THEREFORE, THE MOST PROMISING APPROACH TO PROPHYLAXIS OF RSV DISEASE IN HIGH RISK INFANTS IS PASSIVE IMMUNIZATION. CURRENTLY, INTRAVENOUS HYPERIMMUNE GLOBULIN PREPARED FROM PLASMA CONTAINING HIGH LEVELS OF ANTI-RSV ANTIBODY IS BEING TESTED IN HIGH RISK CHILDREN FOR PROTECTIVE EFFICACY. HOWEVER, A MORE RELIABLE SOURCE OF A HIGHLY DEFINED AND STANDARDIZED PRODUCT WOULD BE DESIRABLE. MURINE MABS AGAINST THE F GLYCOPROTEIN OF RSV HAVE BEEN DEVELOPED AND CHARACTERIZED. THESE HAVE BEEN SHOWN TO NEUTRALIZE RSV IN VITRO AND PROTECT COTTON RATS FROM LOWER RESPIRATORY TRACT INFECTIONIN VIVO. PREVIOUS STUDIES WITH OTHER RODENT ANTIBODIES SUGGEST THAT THE DEVELOPMENT OF HUMAN ANTI-MOUSE ANTIBODY RESPONSES WOULD PRECLUDE THE USE OF THESE MURINE ANTIBODIES DIRECTLY IN CHILDREN. THEREFORE, IT IS THE OBJECTIVE OF THIS PHASE I STUDY TO DEVELOP HUMANIZED DERIVATIVES OF THESE ANTI-RSV ANTIBODIES WHICH COULD THEN BE DEVELOPED AS AGENTS FOR PASSIVE IMMUNIZATION AGAINST RSV INFECTION.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government